(Q36106831)

12 August 2017

1 reference

title

Emerging roles for atypical antipsychotics in chronic post-traumatic stress disorder (English)

1 reference

post-traumatic stress disorder

12 August 2017

0 references

author name string

Mark B Hamner

series ordinal

1

1 reference

PubMed ID

15853496

12 August 2017

Sophie Robert

series ordinal

2

1 reference

12 August 2017

1 March 2005

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

267-275

1 reference

12 August 2017

2

1 reference

Posttraumatic stress disorder in the National Comorbidity Survey

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Linking posttraumatic stress disorder and psychosis: a look at epidemiology, phenomenology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Traumatic life events and PTSD among women with substance use disorders and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

The ACTH response to dexamethasone in PTSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Association between the dopamine transporter gene and posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

The DRD2 gene in psychiatric and neurological disorders and its phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Substance use disorders in patients with posttraumatic stress disorder: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Clinician-administered PTSD scale: a review of the first ten years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Research on posttraumatic stress disorder: epidemiology, pathophysiology, and assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

New medication strategies for comorbid substance use and bipolar affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Off-label indications for atypical antipsychotics: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

The effectiveness of atypical antipsychotic medications in depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

What's atypical about atypical antipsychotic drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

PTSD and comorbid psychotic disorder: comparison with veterans diagnosed with PTSD or psychotic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Quetiapine therapy for posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Olanzapine treatment for post-traumatic stress disorder: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Olanzapine in the treatment of post-traumatic stress disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

Chronic Sleep Disruption and the Reexperiencing Cluster of Posttraumatic Stress Disorder Symptoms Are Improved by Olanzapine: Brief Review of the Literature and a Case-Based Series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.2.267

21 January 2018

Identifiers

DOI

10.1586/14737175.5.2.267

1 reference

12 August 2017

1 reference

PubMed ID

15853496